Targazyme is a clinical-stage biopharmaceutical company that has developed an immunotherapy technology designed to enhance the therapeutic value of any cell-based therapy. Their most advanced product, TZ101, improves the therapeutic potential of cells by enhancing migration to selective sites in the body and improving retention in tissue, which will increase the effectiveness of the cells in numerous disease indications. The company's target indications include cancer, ischemic diseases like heart failure, critical limb ischemia and diabetic retinopathy, and radiation sickness, each of which represents a large market with significant opportunity to improve outcomes for patients. Since its founding in 2005, Targazyme has received funding from angel investors, the management team, and several non-profit and governmental institutions.